Andrey N. Ryabikov

Andrey N. Ryabikov

Auto-generated profile, based on publicly available information

Andrey N. Ryabikov

Research Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2012 in Cardiovascular Ultrasound
Verified
Journal Article
Open access
PDF file
MKMalgorzata Kloch-Badelek
Malgorzata Kloch-Badelek
TKTatiana Kuznetsova
Tatiana Kuznetsova
WSWojciech Sakiewicz
Wojciech Sakiewicz
VTValerie Tikhonoff
Valerie Tikhonoff
ARAndrew Ryabikov
Andrew Ryabikov
TIthe European Project On Genes in Hypertension (EPOGH) Investigators
the European Project On Genes in Hypertension (EPOGH) Investigators
Background: Different diagnostic criteria limit comparisons between populations in the prevalence of diastolic left ventricular (LV) dysfunction. We aimed to compare across populations age-specific echocardiographic criteria for diastolic LV dysfunction as well as their correlates and prevalence. Methods: We measured the E and A peaks of transmitral blood flow by pulsed wave Doppler and the e' and a' peaks of mitral annular velocities by tissue Doppler imaging (TDI) in 2 cohorts randomly recruited in Belgium (n = 782; 51.4% women; mean age, 51.1 years) and in Italy, Poland and Russia (n = 476; 55.7%; 44.5 years). Results: In stepwise regression, the multivariable-adjusted correlates of the transmitral and TDI diastolic indexes were similar in the 2 cohorts and included sex, age, body mass index, blood pressure and heart rate. Similarly, cut-off limits for the E/A ratio (2.5th percentile) and E/e' ratio (97.5th percentile) in 338 and 185 reference subjects free from cardiovascular risk factors respectively selected from both cohorts were consistent within 0.02 and 0.26 units (median across 5 age groups). The rounded 2.5th percentile of the E/A ratio decreased by ~0.10 per age decade in these apparently healthy subjects. The reference subsample provided age-specific cut-off limits for normal E/A and E/e' ratios. In the 2 cohorts combined, diastolic dysfunction groups 1 (impaired relaxation), 2 (possible elevated LV filling pressure) and 3 (elevated E/e' and abnormally low E/A) encompassed 114 (9.1%), 135 (10.7%), and 40 (3.2%) subjects, respectively. Conclusions: The age-specific criteria for diastolic LV dysfunction were highly consistent across the study populations with an age-standardized prevalence of 22.4% vs. 25.1%.

25 January 2021 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
EBErnest Diez Benavente
Ernest Diez Benavente
FJFrancisco Jimenez-Lopez
Francisco Jimenez-Lopez
ZAZachi I. Attia
Zachi I. Attia
SMSofia Malyutina
Sofia Malyutina
AKAlexander V. Kudryavtsev
Alexander V. Kudryavtsev
DLDavid A. Leon
David A. Leon
Background: A non-invasive, easy-to-access marker of accelerated cardiac ageing would provide novel insights into the mechanisms and aetiology of cardiovascular disease (CVD) as well as contribute to risk stratification of those who have not had a heart or circulatory event. Our hypothesis is that differences between an ECG-predicted and chronologic age of participants (δage) would reflect accelerated or decelerated cardiovascular ageing Methods: A convolutional neural network model trained on over 700,000 ECGs from the Mayo Clinic in the U.S.A was used to predict the age of 4,542 participants in the Know Your Heart study conducted in two cities in Russia (2015-2018). Thereafter, δage was used in linear regression models to assess associations with known CVD risk factors and markers of cardiac abnormalities. Results: The biomarker δage (mean: +5.32 years) was strongly and positively associated with established risk factors for CVD: blood pressure, body mass index (BMI), total cholesterol and smoking. Additionally, δage had strong independent positive associations with markers of structural cardiac abnormalities: N-terminal pro b-type natriuretic peptide (NT-proBNP), high sensitivity cardiac troponin T (hs-cTnT) and pulse wave velocity, a valid marker of vascular ageing. Conclusion: The difference between the ECG-age obtained from a convolutional neural network and chronologic age (δage) contains information about the level of exposure of an individual to established CVD risk factors and to markers of cardiac damage in a way that is consistent with it being a biomarker of accelerated cardiovascular (vascular) ageing. Further research is needed to explore whether these associations are seen in populations with different risks of CVD events, and to better understand the underlying mechanisms involved.

25 March 2022 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
MSMarina Shapkina
Marina Shapkina
EME. V. Mazdorova
E. V. Mazdorova
EAE. M. Avdeeva
E. M. Avdeeva
LSL. V. Shcherbakova
L. V. Shcherbakova
ARA. N. Ryabikov
A. N. Ryabikov
SMSofia Malyutina
Sofia Malyutina
Aim. To study the prevalence of atrial fibrillation (AF) in the Russian urban population cohort aged 45-69 years and its changes over 13-year follow-up during aging.Material and methods. This cross-sectional long-term prospective study included random population sample of men and women 45-69 years (n=9360, HAPIEE project, Novosibirsk), which was examined in 2003-2005 and was re-examined twice and followed up for about 13±1,00 years in men and 13,1±2,17 years in women. The incidence of AF was assessed for individuals without AF or cardiovascular disease (CVD) at the baseline examination. Statistical analysis was performed using the SPSS software package (v.13.0).Results. In a population sample over a 13-year follow-up, AF prevalence increased from 1,6% (1,1% among women and 2,1% among men) at the age of 45-69 years to 4,2% (3,0% among women and 6,1% among men) aged 55-84 years according to screening rest ECG examinations. The prevalence of new AF cases over a 13-year followup in the cohort of 45-69 years old without previous CVD and AF was 5,6%, of which 40% were paroxysmal. The mean age at the time of first registered AF was 69±6,93 years, and was 2 years higher in women (70,0±6,83) than in men (68±6,93). The average period before the AF onset among people aged 45-69 years without baseline CVD and AF was 7,5±3,83 years for men and 8,1±4,02 years for women. The total prevalence of AF in the population sample was 8,3%. The highest AF prevalence was registered at the age of 65-69 years (11,4%) for men and 5 years later for women (12,0%) (p80 years decreased and amounted to 4,1% among men and 5,7% among women.Conclusion. In the Russian population sample (Novosibirsk) aged 45-69, the AF prevalence increased from 1,6 to 8,3% over 13 years of follow-up. In addition, 473 new AF cases were identified, ~40% of which were paroxysmal AF. The prevalence of AF in the Siberian population sample for the 45-60 years age group is comparable with the large Russian and North American studies, but higher for persons aged 60-74 years and lower for older age group, for both men and women.

30 December 2022 in Biology
Verified
Journal Article
Open access
PDF file
OCOlga Chervova
Olga Chervova
ECElizabeth Chernysheva
Elizabeth Chernysheva
KPKseniia Panteleeva
Kseniia Panteleeva
TWTyas Arum Widayati
Tyas Arum Widayati
NHNatalie Hrbkova
Natalie Hrbkova
SBStephan Beck
Stephan Beck
We evaluated associations between nine epigenetic age acceleration (EAA) scores and 18 cardiometabolic phenotypes using an Eastern European ageing population cohort richly annotated for a diverse set of phenotypes (subsample, n = 306; aged 45–69 years). This was implemented by splitting the data into groups with positive and negative EAAs. We observed strong association between all EAA scores and sex, suggesting that any analysis of EAAs should be adjusted by sex. We found that some sex-adjusted EAA scores were significantly associated with several phenotypes such as blood levels of gamma-glutamyl transferase and low-density lipoprotein, smoking status, annual alcohol consumption, multiple carotid plaques, and incident coronary heart disease status (not necessarily the same phenotypes for different EAAs). We demonstrated that even after adjusting EAAs for sex, EAA–phenotype associations remain sex-specific, which should be taken into account in any downstream analysis involving EAAs. The obtained results suggest that in some EAA–phenotype associations, negative EAA scores (i.e., epigenetic age below chronological age) indicated more harmful phenotype values, which is counterintuitive. Among all considered epigenetic clocks, GrimAge was significantly associated with more phenotypes than any other EA scores in this Russian sample.

3 May 2020 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
SMSofia Malyutina
Sofia Malyutina
EME. V. Mazdorova
E. V. Mazdorova
MSMarina Shapkina
Marina Shapkina
EAElena Avdeeva
Elena Avdeeva
NMN. A. Maslacov
N. A. Maslacov
ARA. N. Ryabikov
A. N. Ryabikov
Objective To analyze a profile of hypotensive drug therapy in patients with arterial hypertension (АH) aged 55–84 in a sample of urban population at a current period of time (2015–2017). Materials and Methods AH is a leader among risk factors of cardiovascular diseases (CVD) due to its high prevalence and serious prognosis. Despite the availability of effective hypotensive drugs and guidelines on AH treatment, 50% of patients do not achieve blood pressure (BP) goals. Knowledge about drug correction of AH in the Russian population is limited to clinical studies. Taking into account changing approaches in management of patients with AH, the population-based evaluation of hypotensive treatment if relevant. A random population sample of males and females aged 55-84 (n=3.898) was evaluated in Novosibirsk in 2015-2017 (international project, Health, Alcohol and Psychosocial Factors in Eastern Europe (HAPIEE)). AH was diagnosed in presence of systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg and/or treatment with hypotensive drugs within the recent two weeks. Regular intake of medication for 12 months was evaluated with coding according to the Anatomic Therapeutic Chemical Classification System (АТХ / АТС). Results In the population sample aged 55–84, AH prevalence was 80.9 %, and 21.1 % of persons with AH did not receive drug therapy. Hypotensive medicines included (total/as a part of combination therapy) angiotensin-converting enzyme (ACE) inhibitors (42.3 % / 25.3 %), angiotensin II receptor blockers (ARBs) (30.3 % / 18.9 %), diuretics (22.6 % / 20.4 %), calcium channel blockers (20.2 % / 16.1 %), and beta-blockers (34.7 % / 27.6 %). 45.7 % of people with AH received a combination therapy. Effective BP control was achieved in 23.4 % of AH patients and in 29.6 % of patients receiving a hypotensive therapy. In the group of ineffective BP control, the proportion of females was lower, AH duration was longer, and blood glucose was higher than in the group of effective control. Conclusion In the sample of urban population aged 55–84 in 2015–2017, each fourth participant with AH and each third participant using hypotensive drugs achieved effective BP control. The therapy profile in AH patients included recommended drug classes. However, combination therapy was used insufficiently (50% of AH patients). By frequency of use, ACE inhibitors were on the first place, beta-blockers were on the second place, ARBs were on the third place, diuretics were on the fourth place, and calcium channel blockers were on the fifth place, which differed from the guidelines (the difference from the recommended priority ranking is that the drugs taking the first places in the guidelines were in fact on the 3rd and 4th places in their actual frequency of use). 20% of persons with AH did not receive hypotensive therapy, which significantly contributed to the insufficient BP control in the population.

1 July 2011 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
ARAndrew Ryabikov
Andrew Ryabikov
SMSofia Malyutina
Sofia Malyutina
JHJulian Halcox
Julian Halcox
YNYuri Nikitin
Yuri Nikitin
MMMichael Marmot
Michael Marmot
MBMartin Bobak
Martin Bobak
Objective—: Carotid intima-media thickness (IMT) and plaques are markers of atherosclerosis and predict cardiovascular events. A specific sonographic triple line pattern (TLP) of the carotid wall has been identified in different conditions, but its origin and clinical significance are unclear. We examined the prevalence and predictors of TLP in a general population. Methods and Results—: The study was conducted in random sample of the general population of Novosibirsk, Russia, within the international Health, Alcohol and Psychosocial Factors in Eastern Europe project. In a subsample of 418 men (aged 45 to 69), carotid IMT, the presence of atherosclerotic plaques, and the presence of TLP were assessed by ultrasound. The prevalence of TLP was 21%. It was associated with IMT (odds ratio=9.53 per 1 SD, P <0.001) and the presence of plaques (odds ratio=2.42, P =0.002). Other predictors of TLP in multivariate models included age, systolic blood pressure, total cholesterol, and smoking. In addition, infrequent consumption of high amounts of alcohol approximately doubled the risk of triple pattern. Conclusion—: Our findings showed high prevalence of TLP of carotid wall in a general male population sample from a typical Russian city. This sonographic pattern was strongly associated with cardiovascular risk factors and diseases, bioimaging indicators of atherosclerosis, and episodic heavy drinking.